George D Dangas, Mscai

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1198331/publications.pdf

Version: 2024-02-01

313 papers	20,844 citations	22099 59 h-index	11030 137 g-index
557 all docs	557 docs citations	557 times ranked	18293 citing authors

#	Article	IF	Citations
1	Myocardial infarction after cardiac surgery: When to intervene?. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 1195-1201.	0.4	6
2	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. EuroIntervention, 2023, 19, e807-e831.	1.4	5
3	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2022, 43, e17-e25.	1.0	92
4	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. Journal of Thrombosis and Thrombolysis, 2022, 53, 380-389.	1.0	4
5	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 492-502.	1.4	22
6	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. Journal of Thrombosis and Thrombolysis, 2022, 53, 20-29.	1.0	8
7	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. Nature Reviews Cardiology, 2022, 19, 195-208.	6.1	34
8	SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 557-567.	1.4	20
9	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology, 2022, , .	0.7	0
10	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI. JACC: Cardiovascular Interventions, 2022, 15, 282-293.	1.1	6
11	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. American Journal of Cardiology, 2022, 168, 47-54.	0.7	4
12	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention. Canadian Journal of Cardiology, 2022, 38, 792-800.	0.8	2
13	Endothelial Progenitor Cells in Coronary Atherosclerosis and Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2022, 42, 94-99.	0.3	5
14	Timing of mechanical circulatory support during primary angioplasty in acute myocardial infarction and cardiogenic shock: Systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, , .	0.7	5
15	Is cardiac surgery backup required for left main stenting?. Catheterization and Cardiovascular Interventions, 2022, 99, 607-608.	0.7	0
16	Left Ventricular Thrombus Following Acute Myocardial Infarction. Journal of the American College of Cardiology, 2022, 79, 1010-1022.	1.2	53
17	Outcomes in Valve-in-Valve Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2022, 172, 81-89.	0.7	11
18	Outcomes and feasibility of redoâ€TAVR after Sapien 3 Ultra TAVR in extremelyâ€undersizedÂversus nominallyâ€sized annuli. Catheterization and Cardiovascular Interventions, 2022, 99, 1935-1944.	0.7	3

#	Article	IF	Citations
19	Randomized Clinical Trial on Prevention of Radial Occlusion After Transradial Access Using Nitroglycerin. JACC: Cardiovascular Interventions, 2022, 15, 1009-1018.	1.1	8
20	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 707-716.	1.4	5
21	Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement: Additional Data, Yet Still Many Unanswered Questions. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS122011828.	1.4	1
22	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study. EuroIntervention, 2022, 17, 1330-1339.	1.4	5
23	Sex-Related Outcomes of Medical, Percutaneous, and Surgical Interventions for CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2022, 79, 1407-1425.	1.2	21
24	Long-Term Clinical Impact of Contrast-Associated Acute Kidney Injury Following PCI. JACC: Cardiovascular Interventions, 2022, 15, 753-766.	1.1	31
25	Perioperative Management of P2Y12 Inhibitors in Patients Undergoing Cardiac Surgery within 1 Year of PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, , .	1.4	2
26	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry). American Journal of Cardiology, 2022, 172, 73-80.	0.7	4
27	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120009495.	1.4	4
28	Double kissing crush stenting: No pain, no gain?. Catheterization and Cardiovascular Interventions, 2022, 99, 1045-1046.	0.7	0
29	Colchicine in Cardiovascular Disease: In-Depth Review.. Circulation, 2022, 145, 61-78.	1.6	37
30	Tailoring the therapy to the patient with mitral and tricuspid regurgitation to avoid adverse longâ€term outcomes. Catheterization and Cardiovascular Interventions, 2022, 99, 1857-1858.	0.7	0
31	A Biomarkerâ€Enhanced Model for Prediction of Acute Kidney Injury and Cardiovascular Risk Following Angiographic Procedures: CASABLANCA AKI Prediction Substudy. Journal of the American Heart Association, 2022, 11, e025729.	1.6	4
32	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
33	Contrastâ€associated acute kidney injury: Type may not matter. Catheterization and Cardiovascular Interventions, 2022, 100, 94-95.	0.7	0
34	Safety and efficacy of the bioabsorbable polymer everolimusâ€eluting stent versus durable polymer drugâ€eluting stents in highâ€risk patients undergoing PCI : TWILIGHTâ€SYNERGY. Catheterization and Cardiovascular Interventions, 2021, 97, 63-71.	0.7	6
35	Sex differences in 1â€year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2021, 97, 797-804.	0.7	4
36	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. International Journal of Cardiology, 2021, 322, 65-69.	0.8	3

#	Article	IF	Citations
37	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WINâ€TAVI registry. Catheterization and Cardiovascular Interventions, 2021, 97, E704-E715.	0.7	8
38	Prevalence and prognostic impact of hsCRP elevation are ageâ€dependent in women but not in men undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2021, 97, E936-E944.	0.7	3
39	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. International Journal of Cardiology, 2021, 329, 67-73.	0.8	11
40	Radial versus femoral access for coronary interventions: An updated systematic review and metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, 1387-1396.	0.7	42
41	Selection of the Optimal Candidate to MitraClip for Secondary Mitral Regurgitation: Beyond Mitral Valve Morphology. Frontiers in Cardiovascular Medicine, 2021, 8, 585415.	1.1	8
42	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions, 2021, 14, 444-456.	1.1	27
43	<scp>TAVR</scp> for aortic regurgitation: Not as straightforward!. Catheterization and Cardiovascular Interventions, 2021, 97, 486-487.	0.7	1
44	Hemoglobin A1c and Cardiovascular Outcomes Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2021, 14, 388-397.	1.1	14
45	Combination antiplatelet/antithrombotic regimens after stenting: Are we forcing too much in this decision?. Catheterization and Cardiovascular Interventions, 2021, 97, 589-590.	0.7	0
46	Anatomic classification of mitral annular calcification for surgical and transcatheter mitral valve replacement. Journal of Cardiac Surgery, 2021, 36, 2410-2418.	0.3	9
47	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. Clinical Research in Cardiology, 2021, 110, 649-657.	1.5	7
48	Subacute Aortic Root and Valve Thrombosis following Transcatheter Aortic Valve Replacement in a Left Ventricular Assist Device Patient: From One Problem to the Next. Case, 2021, 5, 97-100.	0.1	3
49	Chronic coronary total occlusions: Let's make the long story short. Catheterization and Cardiovascular Interventions, 2021, 97, 1184-1185.	0.7	0
50	Impact of sex on longâ€term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2021, 98, E494-E500.	0.7	2
51	Impact of anemia on shortâ€term outcomes after TAVR : A subgroup analysis from the BRAVO â€3 randomized trial. Catheterization and Cardiovascular Interventions, 2021, 98, E870-E880.	0.7	2
52	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. BMJ, The, 2021, 373, n1332.	3.0	144
53	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. Catheterization and Cardiovascular Interventions, 2021, 98, E908-E917.	0.7	7
54	Shock indices in acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 98, 95-96.	0.7	0

#	Article	IF	Citations
55	Single antiplatelet therapy after transcatheter aortic valve implantation: clarity on existing data. European Heart Journal, 2021, 42, 3203-3204.	1.0	1
56	Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. Catheterization and Cardiovascular Interventions, 2021, 98, 904-913.	0.7	3
57	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2021, 14, 1688-1703.	1.1	31
58	Types of myocardial injury and mid-term outcomes in patients with COVID-19. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 438-446.	1.8	28
59	Patient-specific computational simulation of coronary artery bifurcation stenting. Scientific Reports, 2021, 11, 16486.	1.6	13
60	Assessing the risk of acute kidney injury after primary PCI: The simpler the sooner the better. Catheterization and Cardiovascular Interventions, 2021, 98, 206-207.	0.7	0
61	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. Catheterization and Cardiovascular Interventions, 2021, 98, E785-E795.	0.7	2
62	Coronary access after valveâ€inâ€valve transcatheter aortic valve replacement: Time for a prospective study?. Catheterization and Cardiovascular Interventions, 2021, 98, 605-606.	0.7	0
63	Balloon-Expandable versus Self-Expandable Valves in Transcatheter Aortic Valve Implantation: Complications and Outcomes from a Large International Patient Cohort. Journal of Clinical Medicine, 2021, 10, 4005.	1.0	7
64	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention. JAMA Cardiology, 2021, 6, 1032.	3.0	27
65	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria. Circulation: Cardiovascular Interventions, 2021, 14, e010392.	1.4	6
66	Cusp Overlap Technique: Should It Become the Standard Implantation Technique for Self-expanding Valves?. Current Cardiology Reports, 2021, 23, 154.	1.3	14
67	Sodium Bicarbonate, Contrast-Associated Acute Kidney Injury, and Long-Term Outcomes: The End of an Era?. Cardiovascular Revascularization Medicine, 2021, 31, 69-70.	0.3	0
68	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. European Heart Journal, 2021, 42, 4624-4634.	1.0	54
69	Coronary Dissection and Right Heart Failure Salvaged by PCI With Percutaneous Intraluminal Microaxial RV-Assist Support. JACC: Case Reports, 2021, 3, 1612-1616.	0.3	0
70	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. Circulation, 2021, 144, 1323-1343.	1.6	35
71	Dual versus single antiplatelet therapy after TAVR: Let's not mix apples and oranges. Cardiovascular Revascularization Medicine, 2021, 34, 54-54.	0.3	0
72	Prevalence and Impact of High Bleeding Risk in Patients Undergoing Left Main Artery Disease PCI. JACC: Cardiovascular Interventions, 2021, 14, 2447-2457.	1.1	3

#	Article	IF	Citations
73	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet, The, 2021, 398, 1974-1983.	6.3	69
74	Risk prediction in cardiogenic shock. Catheterization and Cardiovascular Interventions, 2021, 98, 1285-1286.	0.7	0
75	Periprocedural myocardial infarction: multiple definitions and still a quest for consensus. European Heart Journal, 2021, , .	1.0	1
76	291 Ticagrelor monotherapy after percutaneous coronary intervention in high-risk patients with prior myocardial infarction: a prespecified twilight substudy. European Heart Journal Supplements, 2021, 23, .	0.0	0
77	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 120-129.	13.9	362
78	Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement. New England Journal of Medicine, 2020, 382, 130-139.	13.9	194
79	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. American Heart Journal, 2020, 219, 1-8.	1.2	27
80	Impact of stent diameter on outcomes following percutaneous coronary intervention with secondâ€generation drugâ€eluting stents: Results from a large singleâ€center registry. Catheterization and Cardiovascular Interventions, 2020, 96, 558-564.	0.7	6
81	Trends and Outcomes of Intravascular Imaging-guided Percutaneous Coronary Intervention in the United States. Critical Pathways in Cardiology, 2020, 19, 69-74.	0.2	8
82	Clinical outcomes after TAVR with heparin or bivalirudin as periprocedural anticoagulation in patients with and without peripheral arterial disease: Results from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2020, 96, E377-E386.	0.7	5
83	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	0.7	0
84	Viral Coagulopathy in Patients With COVID-19: Treatment and Care. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962093677.	0.7	64
85	Excimer laser coronary atherectomy for uncrossable coronary lesions. A multicenter registry. Catheterization and Cardiovascular Interventions, 2020, 98, 1241-1249.	0.7	13
86	Third-Generation Balloon and Self-Expandable Valves for Aortic Stenosis in Large and Extra-Large Aortic Annuli From the TAVR-LARGE Registry. Circulation: Cardiovascular Interventions, 2020, 13, e009047.	1.4	24
87	Transpulmonary electrotherapy for reduction of lung viral load of SARS-CoV-2 in patients with COVID-19. Medical Hypotheses, 2020, 143, 110071.	0.8	4
88	Characterization of Myocardial Injury in Patients With COVID-19. Journal of the American College of Cardiology, 2020, 76, 2043-2055.	1.2	303
89	Bioprosthetic Valve Thrombosis: Insights from Transcatheter and Surgical Implants. Structural Heart, 2020, 4, 382-388.	0.2	4
90	Rolling the rock uphill during left main stenting: The Sisyphus myth in percutaneous coronary intervention?. Catheterization and Cardiovascular Interventions, 2020, 96, 762-763.	0.7	0

#	Article	IF	Citations
91	Oneâ€year clinical outcomes in patients with chronic kidney disease treated with COMBO stents: From the COMBO collaboration. Catheterization and Cardiovascular Interventions, 2020, , .	0.7	0
92	Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 383, e66.	13.9	7
93	Targeted, Site-Specific, Delivery Vehicles of Therapeutics for COVID-19 Patients. Brief Review. Clinical and Applied Thrombosis/Hemostasis, 2020, 26, 107602962095491.	0.7	9
94	Prognostic Impact of High-Sensitivity C-Reactive Protein in Patients Undergoing Percutaneous Coronary Intervention According to BMI. JACC: Cardiovascular Interventions, 2020, 13, 2882-2892.	1.1	6
95	Stent Technology Reaches Maturity?. JACC: Cardiovascular Interventions, 2020, 13, 2879-2881.	1.1	1
96	Early Adverse Impact of Transfusion After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2020, 13, e009026.	1.4	17
97	Noncontrast Nephropathy After Percutaneous Mitral Valve Edge-to-Edge Repair. Journal of the American College of Cardiology, 2020, 76, 2474-2476.	1.2	5
98	1-Year Outcomes with COMBO Stents in Small-Vessel Coronary Disease: Subgroup Analysis From the COMBO Collaboration. Cardiovascular Revascularization Medicine, 2020, 21, 1542-1547.	0.3	3
99	Cardiovascular outcomes after percutaneous coronary intervention on bifurcation lesions with moderate to severe coronary calcium: A singleâ€center registry study. Catheterization and Cardiovascular Interventions, 2020, 98, 35-42.	0.7	7
100	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	1.4	21
101	Impact of insulin treated and nonâ€insulinâ€treated diabetes compared to patients without diabetes on 1â€year outcomes following contemporary PCI. Catheterization and Cardiovascular Interventions, 2020, 96, 298-308.	0.7	11
102	Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. JAMA Network Open, 2020, 3, e2013136.	2.8	344
103	Management of acute myocardial injury in patients with confirmed or suspected COVID-19. Atherosclerosis, 2020, 305, 58-60.	0.4	2
104	Combined and independent impact of coronary artery calcification and inflammation on risk for adverse cardiovascular events after percutaneous coronary intervention: Results from a large singleâ€center registry. Catheterization and Cardiovascular Interventions, 2020, 96, E278-E286.	0.7	1
105	Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. Journal of the American College of Cardiology, 2020, 75, 578-586.	1.2	66
106	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVOâ€3 trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	0.7	1
107	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2020, 75, 2403-2413.	1.2	60
108	Ticagrelor With or Without Aspirin After ComplexÂPCI. Journal of the American College of Cardiology, 2020, 75, 2414-2424.	1.2	122

#	Article	IF	Citations
109	Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 255-255.	1.4	48
110	Alignment of Transcatheter Aortic-Valve Neo-Commissures (ALIGN TAVR). JACC: Cardiovascular Interventions, 2020, 13, 1030-1042.	1.1	143
111	Validation of the Academic Research Consortium High Bleeding Risk Definition in Contemporary PCI Patients. Journal of the American College of Cardiology, 2020, 75, 2711-2722.	1.2	139
112	Influence of final kissing balloon inflation on long-term outcomes after PCI of distal left main bifurcation lesions in the EXCEL trial. EuroIntervention, 2020, 16, 218-224.	1.4	20
113	Fourth universal definition of myocardial infarction (2018). European Heart Journal, 2019, 40, 237-269.	1.0	2,687
114	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2019, 12, e007734.	1.4	6
115	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	1.8	2
116	Feasibility of Repeat TAVRÂAfter SAPIEN 3 TAVR. JACC: Cardiovascular Interventions, 2019, 12, 1290-1292.	1.1	49
117	Impact of Initial Evolut Transcatheter Aortic Valve Replacement Deployment Orientation on Final Valve Orientation and Coronary Reaccess. Circulation: Cardiovascular Interventions, 2019, 12, e008044.	1.4	43
118	Why females get better longerâ€term outcomes with TAVR. Catheterization and Cardiovascular Interventions, 2019, 94, 753-754.	0.7	1
119	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. International Journal of Cardiology, 2019, 297, 22-29.	0.8	10
120	Redefining landmarks to improve #safefemoral outcomes. Catheterization and Cardiovascular Interventions, 2019, 94, 376-377.	0.7	0
121	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. JAMA Cardiology, 2019, 4, 1092.	3.0	97
122	Sex Differences in Transfemoral Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2019, 74, 2758-2767.	1.2	71
123	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine, 2019, 381, 2032-2042.	13.9	683
124	Contrast-Associated Acute Kidney Injury. New England Journal of Medicine, 2019, 380, 2146-2155.	13.9	363
125	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1941-1948.	0.7	9
126	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVOâ€3 randomized trial. Catheterization and Cardiovascular Interventions, 2019, 93, 1374-1381.	0.7	35

#	Article	IF	Citations
127	Transfemoral TAVR in Nonagenarians. JACC: Cardiovascular Interventions, 2019, 12, 911-920.	1.1	27
128	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. JACC: Cardiovascular Interventions, 2019, 12, 983-992.	1.1	12
129	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	0.8	8
130	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	1.4	17
131	Transcatheter valves are a viable option for degenerative surgical mitral bioprostheses. Catheterization and Cardiovascular Interventions, 2019, 93, 1095-1096.	0.7	0
132	Predictors, Incidence, and Outcomes of Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation Complicated by Stroke. Circulation: Cardiovascular Interventions, 2019, 12, e007546.	1.4	71
133	Calculated Serum Osmolality, Acute Kidney Injury, and Relationship to Mortality after Percutaneous Coronary Intervention. CardioRenal Medicine, 2019, 9, 160-167.	0.7	13
134	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 42-51.	1.0	5
135	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	0.7	7
136	Temporal trends of survival and utilization of mechanical circulatory support devices in patients with inâ€hospital cardiac arrest secondary to ventricular tachycardia/ventricular fibrillation. Catheterization and Cardiovascular Interventions, 2019, 94, 578-587.	0.7	7
137	Leave nothing behind: Promising results for coronary drugâ€coated balloons in clinical practice. Catheterization and Cardiovascular Interventions, 2019, 93, 189-190.	0.7	1
138	Positioning of self-expanding transcatheter valve prostheses. Catheterization and Cardiovascular Interventions, 2019, 93, 530-531.	0.7	0
139	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	0.7	19
140	Adjunct Pharmacotherapy After Transcatheter Aortic Valve Replacement. Interventional Cardiology Clinics, 2019, 8, 357-371.	0.2	5
141	Interventional Cardiology Education Through StructuredÂCase Reviews. JACC: Case Reports, 2019, 1, 884-885.	0.3	0
142	Nothing aches like a heart. Hellenic Journal of Cardiology, 2019, 60, 247-248.	0.4	0
143	Comparison of balloon-expandable vs. self-expandable valves in patients undergoing transfemoral transcatheter aortic valve implantation: from the CENTER-collaboration. European Heart Journal, 2019, 40, 456-465.	1.0	100
144	Long-Term Survival Following MultivesselÂRevascularization in PatientsÂWith Diabetes. Journal of the American College of Cardiology, 2019, 73, 629-638.	1.2	190

#	Article	IF	Citations
145	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e004945.	0.9	7
146	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	1.4	55
147	The prevalence, predictors and outcomes of guidelineâ€directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2019, 93, E112-E119.	0.7	16
148	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. American Heart Journal, 2019, 207, 10-18.	1.2	7
149	Comparison of Local Versus General Anesthesia Following Transfemoral Transcatheter Self-Expanding Aortic Valve Implantation (from the Transcatheter Valve Therapeutics Registry). American Journal of Cardiology, 2019, 123, 419-425.	0.7	18
150	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	0.8	6
151	The quest for a â€œdiabeticâ€•stent. Catheterization and Cardiovascular Interventions, 2018, 91, 892-893.	0.7	1
152	Guidelines for Patient-Reported Outcomes in Clinical Trial Protocols. JAMA - Journal of the American Medical Association, 2018, 319, 450.	3.8	15
153	Cardiac enzyme elevation after coronary revascularization. Catheterization and Cardiovascular Interventions, 2018, 91, 224-225.	0.7	1
154	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	1.1	22
155	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. Canadian Journal of Cardiology, 2018, 34, 319-329.	0.8	22
156	Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drugâ€eluting stent implantations. Catheterization and Cardiovascular Interventions, 2018, 91, 573-581.	0.7	21
157	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2018, 11, e006144.	1.4	24
158	Coronary chronic total occlusions: How to dilate the tough ones. Catheterization and Cardiovascular Interventions, 2018, 91, 667-668.	0.7	2
159	Assessment of transâ€aortic pressure gradient using a coronary pressure wire in patients with mechanical aortic and mitral valve prostheses. Catheterization and Cardiovascular Interventions, 2018, 92, 193-199.	0.7	1
160	Prevalence, correlates, and impact of coronary calcification on adverse events following PCI with newerâ€generation DES: Findings from a large multiethnic registry. Catheterization and Cardiovascular Interventions, 2018, 91, 859-866.	0.7	69
161	Comparison of Transaortic and Subclavian Approaches for Transcatheter Aortic Valve Replacement in Patients with No Transfemoral Access Options. Structural Heart, 2018, 2, 463-468.	0.2	5
162	Transfemoral PCI skill: Use it or lose it.â€¦.But #RadialFirst. Catheterization and Cardiovascular Interventions, 2018, 92, 842-843.	0.7	4

#	Article	IF	Citations
163	Transcatheter valveâ€inâ€valve for failing bioprosthetic aortic valve: Usually a good idea. Catheterization and Cardiovascular Interventions, 2018, 92, 1412-1413.	0.7	0
164	Left Main PCI With DES Versus CABG. Journal of the American College of Cardiology, 2018, 72, 2823-2825.	1.2	0
165	The quest for the optimal treatment for inâ€stent restenosis. Catheterization and Cardiovascular Interventions, 2018, 92, 300-301.	0.7	1
166	1-Year Clinical Outcomes of All-Comer Patients Treated With the Dual-Therapy COMBO Stent. JACC: Cardiovascular Interventions, 2018, 11, 1969-1978.	1.1	21
167	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. Thrombosis and Haemostasis, 2018, 118, 1997-2005.	1.8	19
168	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillationâ€"Rationale and design of the ENVISAGE-TAVI AF trial. American Heart Journal, 2018, 205, 63-69.	1.2	62
169	Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and metaâ€analysis. Cardiovascular Therapeutics, 2018, 36, e12457.	1.1	8
170	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nature Reviews Cardiology, 2018, 15, 480-496.	6.1	180
171	Complete Revascularization During Primary Percutaneous Coronary Intervention Reduces Death and Myocardial Infarction in Patients With Multivessel Disease. JACC: Cardiovascular Interventions, 2018, 11, 833-843.	1.1	55
172	Effect of a Contrast Modulation SystemÂon Contrast Media Use and the Rate ofÂAcute Kidney Injury After Coronary Angiography. JACC: Cardiovascular Interventions, 2018, 11, 1601-1610.	1.1	31
173	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). American Journal of Cardiology, 2018, 122, 1638-1646.	0.7	19
174	Subtotal Occlusion of Left Anterior Coronary Artery in a Professional Athlete. Cardiology, 2018, 140, 71-73.	0.6	2
175	Net clinical benefit of patent foramen ovale closure in patients with cryptogenic stroke: Meta-analysis and meta-regression of randomized trials. International Journal of Cardiology, 2018, 266, 75-80.	0.8	6
176	Platelet Reactivity and Risk of IschemicÂStroke After Coronary Drug-Eluting StentÂImplantation. JACC: Cardiovascular Interventions, 2018, 11, 1277-1286.	1.1	14
177	Overlapping bio-absorbable scaffolds: Aim for D2D technique?. Catheterization and Cardiovascular Interventions, 2018, 91, 1210-1211.	0.7	0
178	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. American Heart Journal, 2017, 184, 81-87.	1.2	95
179	Impact of Diabetes Mellitus on Ischemic Events in Men and Women After Percutaneous Coronary Intervention. American Journal of Cardiology, 2017, 119, 1166-1172.	0.7	12
180	Cerebral Embolic Protection During TAVR. Journal of the American College of Cardiology, 2017, 69, 465-466.	1.2	88

#	Article	IF	Citations
181	Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI. JAMA Cardiology, 2017, 2, 673.	3.0	6
182	Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents. Journal of the American College of Cardiology, 2017, 69, 3055-3066.	1.2	117
183	Impact of preâ€existing or newâ€onset atrial fibrillation on 30â€day clinical outcomes following transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1027-1037.	0.7	8
184	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. International Journal of Cardiology, 2017, 243, 132-139.	0.8	11
185	Effect of valve design and anticoagulation strategy on 30â€day clinical outcomes in transcatheter aortic valve replacement: Results from the BRAVO 3 randomized trial. Catheterization and Cardiovascular Interventions, 2017, 90, 1016-1026.	0.7	4
186	Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponinâ€Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. Journal of the American Heart Association, 2017, 6, .	1.6	30
187	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and RiskÂfor Adverse EventsÂAmong Patients With and WithoutÂDiabetes Mellitus Receiving Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 645-654.	1.1	17
188	Relation of Baseline Hemoglobin Levels and Adverse Events in Patients With Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage strategY and Harmonizing) Tj ETQq0 0 0 rgBT /Overlock 10 T of Cardiology, 2017, 119, 1710-1716.	0.7	39
189	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. Journal of the American College of Cardiology, 2017, 70, 1846-1857.	1.2	58
190	Reply. Journal of the American College of Cardiology, 2017, 70, 1307.	1.2	0
191	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	32
192	Bioresorbable Vascular Scaffolds inÂWomen. JACC: Cardiovascular Interventions, 2017, 10, 1891-1893.	1.1	1
193	Integrating invasive hemodynamic parameters into risk stratification of acute myocardial infarction and cardiogenic shock. Catheterization and Cardiovascular Interventions, 2017, 90, 396-397.	0.7	0
194	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. International Journal of Cardiology, 2017, 246, 20-25.	0.8	15
195	Bleeding After Aortic Valve ReplacementÂMatters. JACC: Cardiovascular Interventions, 2017, 10, 1447-1448.	1.1	9
196	Thrombo-embolic prevention after transcatheter aortic valve implantation. European Heart Journal, 2017, 38, 3341-3350.	1.0	59
197	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2017, 10, 2017-2025.	1.1	41
198	Ischemiaâ€reperfusion injury and ischemic postâ€conditioning in acute myocardial infarction: Lost in translation. Catheterization and Cardiovascular Interventions, 2017, 90, 1068-1069.	0.7	13

#	Article	IF	Citations
199	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. JAMA Cardiology, 2017, 2, 855.	3.0	25
200	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq0 0 0 rgBT /Overlock 10 T 2017, 120, 904-910.	0.7	10
201	Classification and patterns of bifurcation in-stent restenosis (BISR) in the second generation drug eluting stent era. Hellenic Journal of Cardiology, 2017, 58, 167-168.	0.4	1
202	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	0.7	13
203	Diabetes mellitus and multivessel coronary artery disease: an ongoing battle for an ideal treatment strategy. Annals of Translational Medicine, 2017, 5, 261-261.	0.7	2
204	Culprit-lesion only versus complete multivessel percutaneous intervention in ST-elevation myocardial infarction: A systematic review and meta-analysis of randomized trials. International Journal of Cardiology, 2016, 220, 251-259.	0.8	21
205	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	1.1	54
206	Efficacy and safety of routine thrombus aspiration in patients with <scp>ST</scp>â€segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: An updated systematic review and metaâ€analysis of randomized controlled trials. Catheterization and Cardiovascular Interventions, 2016, 87, 650-660.	0.7	12
207	Statistical Essentials in the Design and Analysis of Clinical Trials. , 2016, , 296-300.		0
208	Right Heart Catheterization and Pulmonary Hemodynamics. , 2016, , 485-490.		0
209	Prosthetic Heart Valve Thrombosis. Journal of the American College of Cardiology, 2016, 68, 2670-2689.	1.2	332
210	Sex-Based Differences in Outcomes With Transcatheter Aortic Valve Therapy. Journal of the American College of Cardiology, 2016, 68, 2733-2744.	1.2	160
211	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. American Journal of Cardiology, 2016, 117, 1703-1713.	0.7	18
212	Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segmentâ€"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2016, 9, e003272.	1.4	13
213	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 674-684.	1.1	51
214	Cerebral Embolism During TranscatheterÂAortic Valve Replacement. Journal of the American College of Cardiology, 2016, 68, 589-599.	1.2	45
215	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. Journal of the American College of Cardiology, 2016, 67, 2224-2234.	1.2	445
216	Art and Science of Cerebrovascular Event Prevention After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2016, 9, .	1.4	11

#	Article	IF	Citations
217	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal, 2016, 182, 125-134.	1.2	108
218	Treatment of Higher-Risk Patients With an Indication for Revascularization. Circulation, 2016, 134, 422-431.	1.6	181
219	Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease. European Heart Journal, 2016, 37, 3440-3447.	1.0	57
220	Correlates and Impact of Coronary ArteryÂCalcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	1.1	32
221	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention WithÂStents. JACC: Cardiovascular Interventions, 2016, 9, 1461-1469.	1.1	37
222	Can Coronary Stent Implantation Complexity Become an Intuitive and UsefulÂFactor to Tailor DAPT Duration?. JACC: Cardiovascular Interventions, 2016, 9, 1447-1449.	1.1	1
223	Neurological Outcomes With Embolic Protection Devices in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC: Cardiovascular Interventions, 2016, 9, 2124-2133.	1.1	58
224	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. American Journal of Cardiology, 2016, 118, 1661-1668.	0.7	6
225	Oneâ€year results of the <scp>ICON</scp> (ionic versus nonâ€ionic contrast to obviate worsening) Tj ETQq1 1 0.784314 rgBT /Over Cardiovascular Interventions, 2016, 87, 703-709.	0.7	9
226	Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study. Journal of Thrombosis and Thrombolysis, 2016, 42, 186-196.	1.0	3
227	Prediction of 1â€year mortality and impact of bivalirudin therapy according to level of baseline risk: A patientâ€level pooled analysis from three randomized trials. Catheterization and Cardiovascular Interventions, 2016, 87, 391-400.	0.7	8
228	Bivalirudin Is Associated With Improved In-Hospital Outcomes Compared With Heparin in Percutaneous Vascular Interventions. Circulation: Cardiovascular Interventions, 2016, 9, e002823.	1.4	11
229	Effect of Chronic Kidney Disease in WomenÂUndergoing Percutaneous CoronaryÂIntervention With Drug-ElutingÂStents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	1.1	31
230	Dual Antiplatelet Therapy Duration: A Review of Current Available Evidence. Clinical Therapeutics, 2016, 38, 961-973.	1.1	1
231	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002995.	1.4	12
232	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2016, 117, 192-200.	0.7	16
233	The current role and future prospects of D-dimer biomarker. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 175-184.	1.4	52
234	Bivalirudin or Heparin Treatment During Transcatheter Valve Interventions: Where are we Now?. Current Pharmaceutical Design, 2016, 22, 1911-1917.	0.9	2

#	Article	IF	Citations
235	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute STâ€segment elevation myocardial infarction: Results of the <scp>HORIZONSâ€AMI</scp> trial. Catheterization and Cardiovascular Interventions, 2015, 85, 335-342.	0.7	22
236	The relationship among extent of lipid-rich plaque, lesion characteristics, and plaque progression/regression in patients with coronary artery disease: a serial near-infrared spectroscopy and intravascular ultrasound study. European Heart Journal Cardiovascular Imaging, 2015, 16, 81-87.	0.5	32
237	Factors Affecting Bleeding and Stent Thrombosis in Clinical Trials Comparing Bivalirudin With Heparin During Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2015, 8, e002789.	1.4	13
238	Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCIâ€"rationale and study design of the prospective observational multicenter AVIATOR 2 registry. American Heart Journal, 2015, 170, 1234-1242.	1.2	4
239	Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2015, 66, 2860-2868.	1.2	116
240	Duration of Dual Antiplatelet Therapy AfterÂDrug-Eluting Stent Implantation. Journal of the American College of Cardiology, 2015, 65, 1298-1310.	1.2	314
241	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 51 Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2015, 116, 845-852.	0.7	32
242	Cerebrovascular Events After a Primary Percutaneous Coronary Intervention Strategy for Acute ST-Segmentâ€" Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	4
243	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention â€" From the PROTECT II randomized trial. International Journal of Cardiology, 2015, 189, 272-278.	0.8	9
244	Meta-Analysis of Trials on Mortality After Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Stable Coronary Heart Disease and Objective Evidence of Myocardial Ischemia. American Journal of Cardiology, 2015, 115, 1194-1199.	0.7	60
245	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. International Journal of Cardiology, 2015, 187, 90-96.	0.8	126
246	Balancing the Risk of Bleeding and Stroke in Patients WithÂAtrial Fibrillation After Percutaneous Coronary Intervention (from the AVIATOR Registry). American Journal of Cardiology, 2015, 116, 37-42.	0.7	28
247	Surgical Revascularization versus Percutaneous Coronary Intervention and Optimal Medical Therapy in Diabetic Patients with Multi-Vessel Coronary Artery Disease. Progress in Cardiovascular Diseases, 2015, 58, 306-315.	1.6	12
248	Impact of Contrast-Induced Acute Kidney Injury After Percutaneous Coronary Intervention on Short- and Long-Term Outcomes. Circulation: Cardiovascular Interventions, 2015, 8, e002475.	1.4	148
249	Real Dilemmas Regarding BloodÂTransfusion. JACC: Cardiovascular Interventions, 2015, 8, 447-449.	1.1	1
250	Sexâ€based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONSâ€AMI trial. Catheterization and Cardiovascular Interventions, 2015, 85, 359-368.	0.7	112
251	TAVR Through Heavily Calcified Aorta Following Atheroma Retrieval With the "Elevator" Technique. Journal of Invasive Cardiology, 2015, 27, E216-9.	0.4	0
252	Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms. Angiology, 2014, 65, 677-682.	0.8	4

#	Article	IF	Citations
253	Prasugrel in NSTEMI. Journal of the American College of Cardiology, 2014, 64, 2572-2574.	1.2	1
254	Effect of Anemia on Frequency of Short- and Long-Term Clinical Events in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). American Journal of Cardiology, 2014, 114, 1823-1829.	0.7	53
255	Long-Term Favorable Coronary Healing After Bioresorbable Scaffold Implantation. Journal of the American College of Cardiology, 2014, 64, 2357-2359.	1.2	0
256	What to Do When a Patient With Coronary Stents NeedsÂSurgery?âˆ—. Journal of the American College of Cardiology, 2014, 64, 2740-2742.	1.2	2
257	Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study. JACC: Cardiovascular Imaging, 2014, 7, 397-405.	2.3	47
258	MaXIMAl Benefits in the Elderly?. Journal of the American College of Cardiology, 2014, 63, 1376-1377.	1.2	1
259	Contrast-induced acute kidney injury after primary percutaneous coronary intervention: results from the HORIZONS-AMI substudy. European Heart Journal, 2014, 35, 1533-1540.	1.0	210
260	Spontaneous coronary artery dissection. International Journal of Cardiology, 2014, 175, 8-20.	0.8	82
261	Prognostic Value of Access Site and Nonaccess Site Bleeding After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 622-630.	1.1	34
262	Incidence, Predictors, and Implications of Reinfarction After Primary Percutaneous Coronary Intervention in ST-Segmentâ€"Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 543-551.	1.4	67
263	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	1.1	159
264	Myocardial Damage After TAVR Assessed With CMR. Journal of the American College of Cardiology, 2014, 64, 358-360.	1.2	3
265	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	6.1	33
266	Long-Term Outcome of PCI Versus CABGÂin Insulin and Nonâ€"Insulin-Treated Diabetic Patients. Journal of the American College of Cardiology, 2014, 64, 1189-1197.	1.2	134
267	Meta-Analysis of Randomized Trials Comparing the Effectiveness of Different Strategies for the Treatment of Drug-Eluting Stent Restenosis. American Journal of Cardiology, 2014, 114, 1339-1346.	0.7	30
268	Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. Current Cardiology Reports, 2014, 16, 450.	1.3	1
269	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	1.2	85
270	Composite Outcomes in Coronary Bypass Surgery Versus Percutaneous Intervention. Annals of Thoracic Surgery, 2014, 97, 1983-1990.	0.7	9

#	Article	IF	Citations
271	Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage) Tj ETQq1 1 0.784314 rgBT /Overlo	0.8	38
272	Second-Generation Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in Patients WithÂDiabetes. JACC: Cardiovascular Interventions, 2014, 7, 494-496.	1.1	4
273	Principles of Interventions in Acute Structural Heart Disease. , 2014, , 198-200.		0
274	Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention, 2014, 10, 312-319.	1.4	22
275	Abstract 18908: Transcutaneous Aortic Valve Replacement - 30 Day and 1 Year Outcomes Using Conscious Sedation in Patients Stratified by STS Risk Score. Circulation, 2014, 130, .	1.6	0
276	Abstract 18678: Transcutaneous Aortic Valve Replacement -Is Anticoagulation Protective?. Circulation, 2014, 130, .	1.6	0
277	Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. Journal of Thrombosis and Thrombolysis, 2013, 35, 483-493.	1.0	24
278	Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. JACC: Cardiovascular Interventions, 2013, 6, 914-922.	1.1	181
279	Evolution of intravascular assessment of coronary anatomy and physiology: from ultrasound imaging to optical and flow assessment. European Journal of Clinical Investigation, 2013, 43, 996-1008.	1.7	15
280	Combination Antithrombotic Management of STEMI with Pharmacoinvasive Strategy, Primary PCI, or Rescue PCI. Interventional Cardiology Clinics, 2013, 2, 573-583.	0.2	0
281	Aspirin, Platelet P2Y12 Receptor Inhibitors, and Other Oral Antiplatelets. Interventional Cardiology Clinics, 2013, 2, 527-535.	0.2	8
282	Interventional Pharmacology. Interventional Cardiology Clinics, 2013, 2, xiii-xiv.	0.2	0
283	Percutaneous recanalization of chronic total occlusions: Wherein lies the body of proof?. American Heart Journal, 2013, 165, 133-142.	1.2	30
284	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. EuroIntervention, 2013, 8, 1033-1039.	1.4	25
285	Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. Atherosclerosis, 2012, 221, 176-182.	0.4	46
286	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. Journal of the American College of Cardiology, 2012, 59, 1752-1759.	1.2	51
287	Open Versus Endovascular Stent Graft Repair of Abdominal Aortic Aneurysms. JACC: Cardiovascular Interventions, 2012, 5, 1071-1080.	1.1	94
288	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	1.1	101

#	Article	IF	Citations
289	Inâ€stent restenosis of bifurcation lesions: Experience with drugâ€eluting balloons. Catheterization and Cardiovascular Interventions, 2012, 79, 397-398.	0.7	1
290	Late Stent Thrombosis: The Last Remaining Obstacle in Coronary Interventional Therapy. Current Cardiology Reports, 2012, 14, 408-417.	1.3	15
291	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 2309-2316.	1.2	49
292	Impact of the Everolimus-Eluting Stent on Stent Thrombosis. Journal of the American College of Cardiology, 2011, 58, 1569-1577.	1.2	258
293	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2011, 58, 1945-1954.	1.2	383
294	To excel or to confirm? That is the question. Catheterization and Cardiovascular Interventions, 2011, 77, 944-944.	0.7	0
295	Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation, 2011, 123, 1745-1756.	1.6	222
296	Endovascular treatment of infrarenal aortic stenosis: importance of multimodality imaging. Journal of Invasive Cardiology, 2011, 23, E192-6.	0.4	0
297	In-Stent Restenosis in the Drug-Eluting Stent Era. Journal of the American College of Cardiology, 2010, 56, 1897-1907.	1.2	663
298	Bifurcation stenting with drug-eluting stents: a systematic review and meta-analysis of randomised trials. EuroIntervention, 2009, 5, 475-484.	1.4	98
299	Contrastâ€induced nephropathy. Catheterization and Cardiovascular Interventions, 2008, 71, 62-72.	0.7	99
300	Bivalirudin during Primary PCI in Acute Myocardial Infarction. New England Journal of Medicine, 2008, 358, 2218-2230.	13.9	1,693
301	A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention. Journal of the American College of Cardiology, 2004, 44, 1393-1399.	1.2	1,127
302	Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention. Circulation, 2001, 104, 642-647.	1.6	207
303	Stroke After Coronary Artery Bypass. Stroke, 2001, 32, 1508-1513.	1.0	299
304	Treatment of In-Stent Restenosis With Excimer Laser Coronary Angioplasty Versus Rotational Atherectomy. Circulation, 2000, 101, 2484-2489.	1.6	140
305	Atherosclerotic Plaque Burden and CK-MB Enzyme Elevation After Coronary Interventions. Circulation, 2000, 101, 604-610.	1.6	256
306	Nonâ€"Q-Wave Infarction and Ostial Left Coronary Obstruction Due to Giant Lamblâ€™s Excrescences of the Aortic Valve. Circulation, 1999, 99, 1919-1921.	1.6	15

#	Article	IF	Citations
307	Angiographic Patterns of In-Stent Restenosis. Circulation, 1999, 100, 1872-1878.	1.6	1,151
308	Percutaneous Transcatheter Management of Giant Coronary Aneurysms. Circulation, 1999, 100, E8-E11.	1.6	15
309	Creatine Kinase-MB Enzyme Elevation Following Successful Saphenous Vein Graft Intervention Is Associated With Late Mortality. Circulation, 1999, 100, 2400-2405.	1.6	217
310	Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course. Journal of the American College of Cardiology, 1999, 34, 663-671.	1.2	123
311	Use of a pneumatic compression system (FEMOSTOPBÂ®) as a treatment option for femoral artery pseudoaneurysms after percutaneous cardiac procedures. Catheterization and Cardiovascular Diagnosis, 1996, 39, 138-142.	0.7	11
312	Statistical Essentials in the Design and Analysis of Clinical Trials. , 0, , 491-501.		0
313	Two years into the COVID-19 pandemic: implications for the cardiac catheterization laboratory and its current practices. Journal of Transcatheter Interventions, 0, , 1-7.	0.1	0